2021-04-01

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

2021-04-01

Crossover Health Raises $168 Million to Grow Primary-Health Services

2021-04-01

Tremeau Pharmaceuticals Will Advance Non-Opioid Pain Program with Investment from Gurnet Point Capital

2020-08-31

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

2020-07-29

Amazentis Launches Timeline™ powered by Mitopure™ A Breakthrough in Cellular Nutrition

2020-04-21

Zikani Therapeutics Completes Series A-1 Funding Company Poised to Advance its TURBO-ZM™ Technology Platform to Develop Novel Ribosome Modulators to Treat Rare Nonsense Mutations

2020-02-28

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL® for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

2020-02-24

Gurnet Point Capital Names David Moore Partner

2020-02-20

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy Therapeutics

2019-10-05

Boston Pharmaceuticals drug enters Phase 1 UK trial in triple-negative breast cancer